FibroBiologics, Inc.

FBLG Nasdaq CIK: 0001958777

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 455 E. MEDICAL CENTER BLVD, HOUSTON, TX, 77598
Mailing Address 455 E. MEDICAL CENTER BLVD SUITE 300, HOUSTON, TX, 77598
Phone 281-671-5150
Fiscal Year End 1231
EIN 863329066

Financial Overview

FY2024

$16.45M
Total Assets
$13.71M
Total Liabilities
$13.98M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events February 6, 2026 View on SEC
8-K Current report of material events January 2, 2026 View on SEC
DEF 14A Definitive proxy statement December 29, 2025 View on SEC
S-1 IPO registration statement December 23, 2025 View on SEC
DEF 14A Definitive proxy statement December 18, 2025 View on SEC
424B5 Prospectus supplement December 15, 2025 View on SEC
8-K Current report of material events December 15, 2025 View on SEC
4 Insider stock transaction report December 12, 2025 View on SEC
8-K Current report of material events November 25, 2025 View on SEC
424B5 Prospectus supplement November 25, 2025 View on SEC

Material Events

8-K Financial Distress February 6, 2026
High Impact
  • FibroBiologics faces dual Nasdaq non-compliance for failing to maintain a minimum share price ($1.00) and market value ($35 million).
  • The company has proposed a reverse stock split (ranging from 1-for-5 to 1-for-30 shares) to regain compliance with Nasdaq rules.
View Analysis
8-K Financial Distress January 2, 2026
High Impact
  • FibroBiologics received a serious warning that its shares might be removed from the Nasdaq stock exchange due to its stock price being too low for too long.
  • The company's stock price has consistently traded below $1.00 per share, violating Nasdaq's minimum bid price rule.
View Analysis

Insider Trading

BUY 1 insiders 1 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.